WASHINGTON — Barzolvolimab, a first-in-class anti-KIT monoclonal antibody, reduced the severity of hives in adults with chronic spontaneous urticaria (CSU) who remained symptomatic on antihistamines, a randomized phase II trial showed.
Compared with placebo, several doses of the investigational drug produced greater improvement in the 7-day Urticaria Activity Score (UAS7) from baseline to week 12:
- Placebo every 4 weeks: least squares mean change -10.47
- 75 mg every 4 weeks: -17.06 (P=0.0017)
- 150 mg every 4 weeks: -23.02 (P